ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms. Co.'s focus is on renal and inflammatory diseases. The lead candidate in Co.'s renal pipeline is a Phase 2a-ready cholesterol efflux mediator, VAR 200, for focal segmental glomerulosclerosis (FSGS), an orphan renal disease. VAR 200 mediates removal of excess renal cholesterol and lipids that damage the kidneys and has potential to reduce proteinuria and delay disease progression. For treatment of inflammatory diseases, Co. is developing a monoclonal antibody that inhibits inflammasome ASC (IC 100). We show 3 historical shares outstanding datapoints in our ZVSA shares outstanding history coverage, used to compute ZVSA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ZVSA market cap history over the course of time is important for investors
interested in comparing ZVSA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ZVSA versus a peer is one thing; comparing
ZVSA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ZVSA can fluctuate over the course of history.
With this page we aim to empower investors researching ZVSA by allowing them to research the ZVSA market cap history. |
Free ZVSA Email Alerts:
Video: The Importance of Market Cap
